Dr. Radhika Counsell, Consulting Medical Officer, offers a deep dive into differentiated thyroid cancers and discusses this topic in the context of critical illness claims assessment in ReFlections.
Thyroid cancer (TC) is the most prevalent endocrine cancer, accounting for about 95% of all such malignancies. The incidence of this cancer has increased dramatically in the last three decades.
The thyroid is a physically insignificant endocrine gland located in the neck anterior to the trachea. Cancer of the thyroid has historically been uncommon, yet incidence rates have been increasing dramatically worldwide over the past 20 years. A corresponding increase in thyroid cancer claims has also been observed in Critical Illness (CI) insurance over the past decade.
Strong arguments support cancer screening in a clinical setting, but for insurers offering Critical Illness (CI) policies it could mean they receive claims for tiny tumors that are anything but serious. Affordable access to sensitive imaging technology has the potential to drive a massive rise in the numbers of insignificant cancers being detected.